Company Overview and News

13
MARKET WRAP: NZ shares climb on Fletchers announcement

2018-06-21 nbr.co.nz
New Zealand shares rose today as Fletcher Building reassured its shareholders and A2 Milk played catchup.
FBU RHCGF FBU FCREY RYHTY RYM FRCEF PFGTF SML

17
Shares gain as market cheers Fletcher Building plans

2018-06-21 nzherald.co.nz
New Zealand shares rallied, pushing the S&P/NZX 50 Index to a record after Fletcher Building detailed its five-year strategy and affirmed guidance. Sky Network Television, A2 Milk, Auckland International Airport and Fisher & Paykel Healthcare rose.
AIA FBU RHCGF FCREY RYM ACKDF FRCEF AUKNY SKT SYKWF AIA PPSHY FBU RYHTY SKKTY SML

5
MARKET WRAP: NZ shares fall as US-NK summit kicks off

2018-06-12 nbr.co.nz
New Zealand shares fell slightly today, as investors and the world watched the unprecedented meeting between North Korean and American leaders unfold in Singapore.
RHCGF RYHTY RYM

13
NZ shares dip in market lull during US-North Korea summit

2018-06-12 nzherald.co.nz
New Zealand shares dipped in light trading as some stocks gave up dividends, with the focus on the US-North Korea summit in Singapore.
KTHDY SKT SYKWF RHCGF THL RYHTY SNZ SKKTY RYM KMD SML KMD

7
MARKET WRAP: NZ shares continue on record run

2018-06-11 nbr.co.nz
Harbour Asset Management analyst Shane Solly says all eyes will be on Trump’s meeting with Kim Jong Un tomorrow.
AIA RHCGF AIA RYHTY RYM ACKDF AUKNY PFGTF

15
Kathmandu leads gains as shares hit record

2018-06-08 nzherald.co.nz
New Zealand shares hit another record, rounding out the week with a 3.5 per cent gain, led higher by Kathmandu Holdings and New Zealand Refining Company.
KTHDY RHCGF AIR RYM NZR ANZFY AIZ KMD ANZLY RYHTY ANZFF KMD SML

5
MS Limited buys “too good” Box Hill HQ

2018-06-07 theage.com.au
Not-for-profit information, advice and support group, Multiple Sclerosis Limited, has paid $9.5 million for a brand new Box Hill office “too good to pass up”.
RHCGF RYHTY RYM

5
MS Limited buys “too good” Box Hill HQ

2018-06-07 smh.com.au
Not-for-profit information, advice and support group, Multiple Sclerosis Limited, has paid $9.5 million for a brand new Box Hill office “too good to pass up”.
RHCGF RYHTY RYM

15
Shares up 1% to new record, A2 and Fletcher gain

2018-06-07 nzherald.co.nz
New Zealand shares surged to a fresh record, led by A2 Milk Co and Fletcher Building amid international demand for Kiwi companies.
KTHDY AIA FBU RHCGF FCREY RYM ACKDF FRCEF AUKNY KWIPF KMD AIA FBU RYHTY KMD

13
NZX 50 rises to record, led by F&P Healthcare

2018-06-06 nzherald.co.nz
New Zealand shares rose, pushing the S&P/NZX 50 Index to a record, as Fisher & Paykel Healthcare extended its gains and investors picked up stocks that are carrying a dividend payment including Ryman Healthcare, Mainfreight and Arvida Group.
FBU RHCGF NZSTY FBU FCREY RYHTY NZSTF RYM FRCEF SML

5
Mark Lister: Market suffers if investors get too excited

2018-06-04 nzherald.co.nz
A feature of the last month has been the market reaction to results from some of our growth businesses.
RHCGF RYHTY RYM

5
Brian Gaynor: NZ's best investor ��� is it BoP Regional Council?

2018-06-01 nzherald.co.nz
Is it Graeme Hart, the Todd family, Sir Ron Brierley, Rod Duke or Sir Robert Jones?
RHCGF RYHTY RYM

7
MARKET WRAP: NZ shares fall on A2 and Comvita losses

2018-05-22 nbr.co.nz
New Zealand shares fell today as Comvita continued its plunge after an end to takeover talks, and A2 Milk took losses.
RHCGF RYHTY RYM SML

14
A2 Milk drops 3 per cent as sharemarket edges lower

2018-05-22 nzherald.co.nz
New Zealand shares fell, led lower by continued selling in A2 Milk Co and Comvita, while Ryman Healthcare and Heartland Bank gained.
KTHDY CEN NMR RHCGF RYM COENY KMD COENF AOTUF 8604 SKC AFP N33 RYHTY NRSCF CEN KMD

5
Ryman Healthcare plans new $100 million retirement village

2018-05-18 nzherald.co.nz
Plans are being made to build a new $100 million retirement village in Havelock North - and residents will get a say on who to name it after.
RHCGF RYHTY RYM

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to NZX:RYM / Ryman Healthcare on message board site Silicon Investor.

RYMER FOODS INC [RYR] SHORT TERM